Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that ginger supplementation significantly improved persistent hypothyroid symptoms and may aid in weight and lipid profile management in hypothyroid patients with normal TSH levels.

This study found that treatment with the synbiotic SIM01 significantly alleviated multiple symptoms of post-acute COVID-19 syndrome compared to placebo, suggesting potential management benefits through gut microbiome modulation.

This study found that spinach-derived thylakoid supplementation, combined with a calorie-restricted diet, led to more significant improvements in weight loss and insulin sensitivity in obese women with PCOS than calorie restriction alone.

This study found that after 12 weeks of taking the trial product SHPro®, participants reported improvements in prostate symptom scores and erectile function, with confirmed safety.

This study observed that cyclosporine showed a trend toward improving alopecia areata symptoms compared to placebo, but the difference was not statistically significant.

This study found that six months of using 0.5% finasteride cream did not significantly reduce hair number or thickness in women with idiopathic facial hirsutism, though patients perceived less hair growth.

This study found that using an oral contraceptive with bicalutamide significantly reduced hirsutism in women with PCOS compared to an oral contraceptive alone, although it increased total cholesterol and LDL levels.

In this study, the authors reported that dutasteride significantly reduced total remission time for COVID-19 symptoms in men compared to placebo, especially for fatigue and loss of taste or smell.

This study found that a 16-week dermal application of rice bran extract significantly increased hair density and diameter in male androgenic alopecia patients without causing adverse reactions.

This study reported that the topical treatment HDMHG0401-10 significantly improved hair density in men with androgenetic alopecia compared to placebo, although subjective hair growth ratings were not significantly different.

This study reported that Cosmerna ARI significantly improved androgenetic alopecia in Europeans over a 6-month period compared to a placebo, according to a double-blind, randomized, placebo-controlled clinical trial.

This study found that recruiting healthy naturally menopausal women for a DHEA therapy trial was challenged by concerns about hormonal treatments and time constraints, impacting study feasibility.

This study found that the dietary supplement RJ-SP4AGA significantly improved hair growth and reduced hair loss in post-menopausal women with androgenetic alopecia over 16 weeks.

In this study, oral spermidine supplementation was found to significantly prolong the hair follicle anagen phase and reduce hair loss, with effects persisting three months after treatment in healthy participants, suggesting potential therapeutic benefits for hair loss conditions.

In a 24-week randomized trial, this study found that the RAMACAP laser helmet significantly increased hair density and diameter in androgenetic alopecia patients compared to a sham device, although limitations included a small sample size and potential issues with the control used.

This study found that transdermal testosterone significantly increased the frequency of satisfactory sexual events in women experiencing SSRI/SNRI-related loss of libido, but did not improve overall sexual self-rating scores.

This study reported that using 5% minoxidil topical foam twice daily improved hair density and width in both the frontotemporal and vertex regions of men with moderate androgenetic alopecia.

In this study, sublingual minoxidil was found to be a safe and effective treatment for increasing hair growth in transgender individuals with mild androgenetic alopecia who are undergoing full-dose testosterone therapy.

This study found that both single- and double-spin PRP preparation methods significantly increased thrombocyte counts and improved hair parameters in males with androgenetic alopecia, with the single-spin method showing a more significant increase in thrombocyte count.

This study found that a new 5% minoxidil foam formulation significantly increased hair counts and improved hair loss condition in men with androgenetic alopecia over 16 weeks compared to placebo.

This study found that low-level light therapy significantly increased hair density and diameter in androgenetic alopecia patients compared to a sham device, suggesting it could be an effective treatment option.

This study found that in males with mild COVID-19, treatment with dutasteride, along with standard therapy, may reduce viral shedding and inflammation compared to placebo.

This study found that oral setipiprant was safe but did not improve scalp hair growth compared to placebo in men with androgenetic alopecia.

In this study, adults with mild-to-moderate hair damage taking GPVGPS Collagen® daily for 24 weeks showed significant improvements in hair luster, strength, thickness, and density compared to placebo, with no safety concerns reported.

In this study, botulinum toxin type A did not improve clinical features in patients with recalcitrant alopecia totalis or alopecia universalis over a four-month period.

This study found that the Hair660™ low-level light therapy device significantly improved hair density and was safe for men with androgenetic alopecia over 24 weeks.

This study found that men with androgenetic alopecia treated with pumpkin seed oil for 24 weeks experienced a notable 40% increase in hair count compared to a 10% increase with a placebo.

In this study, a royal jelly formulation applied for 12 weeks led to significant improvements in hair elongation and gloss among individuals with self-perceived hair thinning, although changes in hair density were mild compared to placebo.

This study suggests that combining silymarin with hair transplantation might be a promising treatment for vitiligo, but more research is needed to confirm its effectiveness.

In this study, clobetasol propionate foam demonstrated effectiveness and good patient compliance as a safe topical treatment for moderate to severe alopecia areata, with significant hair regrowth compared to placebo.